Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Waste Management, Inc. — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Waste Management, Inc. trades at $217.25 (market cap $84.67B). The key difference: Waste Management, Inc. is far larger — about 11.3× Spyre Therapeutics Inc. Common Stock's market cap, and Waste Management, Inc. pays a 1.78% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Waste Management, Inc. for 131 Days on average.
| SYRE | WM | |
|---|---|---|
Market Cap | $7.52B | $84.67B |
Volume | 1,441,031 | 1,534,456 |
Sector | Health | Industrials |
52-Week High | $108.92 | $246.51 |
52-Week Low | $22.18 | $196.77 |
Typical Hold Time | 0 Days | 131 Days |
Enterprise Value | $6.52B | $107.47B |
Dividend Yield | — | 1.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
WM trades at $215.75, up 2.18% today, with a bullish technical signal despite mixed momentum indicators. The company reported strong revenue growth to $25.20 billion in 2025 and beat earnings estimates in two of the last three quarters. Analyst consensus is positive with 54% buy ratings, and the stock offers a dividend yield supported by robust cash flow from operations of $6.04 billion.
Outlook remains favorable due to pricing power and acquisition strategy, but elevated debt levels and a high P/E ratio of 29.96 pose risks. Near-term performance hinges on Q3 2026 earnings results expected on October 27, 2026, with investor focus on margin sustainability and debt management amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
